Increasing the Efficacy of Onabotulinumtoxin A by 200%
Latest research shall be presented at Symposium 43 at IMCAS World Congress 2017, Paris, France on January 26, 2017.
Currently, a Phase 1 trial has been completed with 17 participants from 2013 to 2014 resulting in an average efficacy period of 9 months. As of 2016 No adverse events were reported and no adverse drug reactions were reported. This Phase 1 trial of Onabotulinumtoxin A and Ag4O4 combination has been completed in British Colombia, Canada.
Dr. Andrew JM Willoughby, DMD, discovered a new formulation for BOTOX® (onabotulinumtoxinA) that extends the effective time to over nine months. Dr. Willoughby, a reconstructive and cosmetic based dentist with numerous accreditations and over 30 years of clinical experience. Dr. Willoughby found in 2013, that he could extend the effective time of BOTOX® by over 200%. During 2013 and 2014, a phase 1 (limited) clinical trial was conducted involving 17 healthy, adult participants. The trial involved diluting Botox with a new buffer solution (“diluent”) comprised of a nanometallic silver hydrosol. Dr. Willoughby, found this new buffer solution to be a type of “BOTOX® Bacteriostatic” material.
The results of this discovery were monumental. After closely following the 17 participants for over a year after the initial treatments two exceptional observations were made:
1. The “BOTOX® Bacteriostatic” effect lasted up to 200+% longer with participants/patients previously injected with just Botox. This meant less injections to maintain to the same amount of desired muscle relaxation.
2. The “BOTOX® Bacteriostatic” (diluted) solution appeared to remain stable and preserve it's efficacy for upwards of 3-4 months while refrigerated.
As of the publication of this press release zero adverse events have been reported by all 17 participants.
Dr. Willoughby believes that the pharmacology and cellular mechanism of action behind these results are twofold: 1) it involves the stimulation of the lysol oxidase cascade and connective tissue metabolism which is essential in the physiologic rest potential of every muscle injected with Botox and 2) the manner in which the NMSH molecule is able to encapsulate and preserve a purified protein such as Onabotulinumtoxin A.
Currently, Dr. Willoughby along with Leigh J. Mack, MD, PhD, FAPCR CPI are organizing a formal Phase 2, double blind, factorial clinical trial with 120 participants. A clinical trial start date in 2017 is anticipated.
Dr. Mack believes a possible mechanism of action and the reason for extension of efficacy. The Onabotulinumtoxin A is not being removed by the body as quickly - this may be a reason why:
150-kDa core BoNT is the only part capable of stimulating the formation of neutralizing antibodies. More specifically, Flagellin is a constituent protein of the bacterial locomotor apparatus that interacts with the Toll-Like Receptor 5 (TLR5) which initiates a immune response. Ag4O4 Silversol’s two trivalent bonds , within the particle, creates a small magnetic field that disrupts this communication and hinders the biochemical communication of TLR5 communication. The toll-like receptors then do not send information recognizing the flagellin. This in turn stops MyD88 leading to subsequent activation of IRAK4, IRAK1, TRAF6, and eventually IκB kinases. Activation of IκB kinases contributes to the nuclear localization of NF-κB (a proinflammatory cytokine). NF-κB induces many downstream gene expressions, which initiates the canonical proinflammatory pathway.
Currently we are in the process of funding a full Phase 2 clinical trial in British Columbia for a specific maxillofacial condition. If you are interested in knowing more or interested in investing please contact us directly.
BOTOX® is a registered trademark of Allergan, Inc., Irvine CA. This study was neither funded or approved by Allergan, Inc., Irvine CA.